TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to report the results from its 007 North bulk sample at its wholly-owned Pardo Gold Project, located 65 km northeast of Sudbury, Ontario. Highlights A total of 427 ounces of gold recovered from 4,674 dry tonnes for a reconciled head grade of 3.04 gpt gold and a metallurgical recovery of 94%The cost of the bulk sample was approximately CAD$1,200,000 and the sale of the recoverable ounces was ...

Located just 7 km west of Filo del Sol in the Vicuña District, the 46 South target is at the south end of a 3 km N-S trending corridor of mineralization at Sobek Central The 46 South epithermal and underlying porphyry target sits on the margin of a district scale magnetic high where coincident mag-susceptibility, MT anomalies and ground-based IP responses lie directly below a large soil survey geochemical anomaly where hydrothermal and tourmaline breccias outcrop on surface In preparation for drilling a pro ...

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to be ...

October Revenue Up 128% Year-Over-Year; Net Income Up 169% as Wilson-Davis Continues Strong FY2026 MomentumTAMPA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a technology-enabled financial services platform modernizing trading, clearing, settlement, and banking, today announced that its wholly owned subsidiary, Wilson-Davis & Co. (“WDCO”), has filed its October 2025 FOCUS Report with FINRA, reflecting another month of exceptional g ...

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designat ...

KELOWNA, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)(“Doseology” or the “Company”) is pleased to announce the launch of its Investor Communications Initiative, designed to strengthen disclosure practices, expand investor engagement, and support the Company’s long-term commercial and capital-markets strategy. The program includes a three (3) month engagement with Guerilla Capital, with an option to renew, along with a one (1) year digital ...

TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired the final segment, Part Three, of their three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation. Award-winning CTV News journalist and W5 investigative reporter Jon Woodward provides highlights of Part Three of the series in an a ...

Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transactionARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, announces it has entered into a $6 million securities purchas ...

CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that it has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim®, a drug-free treatment for functional abdominal pain in patients 8 years and ...

MONTREAL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce more results from its inaugural drilling campaign at the Anatacau Main Project, located in the Eeyou Istchee-James Bay region of Quebec. All results have now been received and cement BRW’s latest discovery within its growing portfolio as a high priority target for follow-up drilling. Highlights include: 1.53% Li2O over 53.9 meters in drill hole AN-25-04 at a verti ...